Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685229 | 0.82 | CYP2C9 (0.46) | ERN1TDP1MEN1KMT2ACYP2C9 | |
| SCHEMBL415893 | 0.82 | CYP2C9 (0.46) | ERN1TDP1MEN1KMT2ACYP2C9 | |
| SCHEMBL745181 | 0.80 | ERN1 (0.46) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL1814731 | 0.77 | TDP1 (0.43) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL548457 | 0.76 | TDP1 (0.50) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL4293546 | 0.74 | ERN1 (0.42) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL1359122 | 0.74 | ALDH1A1 (0.50) | ERN1TDP1MEN1LMNAKMT2A | |
| SCHEMBL1042430 | 0.74 | ERN1 (0.63) | ERN1 | |
| SCHEMBL20607708 | 0.74 | ERN1 (0.42) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL1013026 | 0.74 | ERN1 (0.40) | ERN1TDP1MEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915331-B1 | PRODUCTION PROCESS OF NUCLEUS-HALOGENATED METHYLBENZYL ALCOHOL | SHOWA DENKO KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-7939695-B2 | Production process of nucleus-halogenated methylbenzyl alcohol | SHOWA DENKO K.K. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20100145106-A1 | PRODUCTION PROCESS OF NUCLEUS-HALOGENATED METHYLBENZYL ALCOHOL | SHOWA DENKO K.K. (JP) | 2010-06-10 | — | — | US | disclosed |
| EP-1915331-A2 | PRODUCTION PROCESS OF NUCLEUS-HALOGENATED METHYLBENZYL ALCOHOL | Showa Denko K.K. (JP) | 2008-04-30 | — | — | EP | disclosed |
| WO-2006137348-A2 | PRODUCTION PROCESS OF NUCLEUS-HALOGENATED METHYLBENZYL ALCOHOL | SHOWA DENKO K.K. (JP) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145106-A1 | PRODUCTION PROCESS OF NUCLEUS-HALOGENATED METHYLBENZYL ALCOHOL | NPM1, MED1, KPNA2 | ERN1 1831/4885TDP1 3007/4885MEN1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.